All In Biotech

Drug Trial Radar · NCT07323095

Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia

A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Oct 2, 2026

Primary completion

Oct 31, 2027

Study completion Jan 31, 2028

Sponsor

Lead sponsor
Atom Therapeutics Co., LtdIndustry
Sponsor type
Industry
First posted
Jan 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2, international, multicenter, randomized, double blind, placebo-controlled trial to evaluate the efficacy and safety of ABP-671 in subjects with CKD and hyperuricaemia, to preliminarily evaluate the efficacy of ABP-671 in the treatment of subjects with CKD and hyperuricemia, primary Efficacy Endpoint is change in UACR from baseline to Week 40

Conditions

  • Chronic Kidney Disease

Interventions

  • ABP-671 plus febuxostat Group 1Drug

    ABP-671 Dose 1 + Febuxostat Dose 1-tablets(PO)

  • ABP-671 plus febuxostat Group 2Drug

    ABP-671 Dose 2 + Febuxostat Dose 2-tablets(PO)

  • ABP-671 GroupDrug

    ABP-671 Dose 2 + Febuxostat placebo-tablets(PO)

  • Placebo GroupDrug

    ABP-671 placebo-tablets(PO) + Febuxostat placebo-tablets(PO)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change in the urine albumin-to-creatinine ratio (mg/g) as reported in the laboratory report compared to the baselineTime frame: Week 40

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Renal Research Gosford Pty Ltd

    Gosford, New South Wales, Australia · Not yet recruiting

  • Genesis Research services

    Newcastle, New South Wales, Australia · Recruiting

  • Paratus Clinical Research Brisbane

    Brisbane, Queensland, Australia · Recruiting

  • Beijing Tsinghua Changgung Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Peking University First Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Xuanwu Hospital Capital Medical University

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Sir Run Run Shaw Hospital , affiliated with the Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Not yet recruiting

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.